Regulatory Sweep Targets Cipla’s Mumbai Hub Over Drug Classification
The Directorate of Revenue Intelligence conducted searches at Cipla’s Mumbai office and its Bhiwandi depot, probing the classification of imported pharmaceuticals. Cipla asserted full cooperation and warned that the operation would not materially affect its financial performance or day‑to‑day activities.

On a quiet morning in Mumbai, officers from the Directorate of Revenue Intelligence entered Cipla’s corporate premises and a nearby depot in Bhiwandi, seeking answers about the regulatory status of certain imported drug batches. The search, prompted by concerns that the medicines might have been mis‑classified to evade higher duties, marked a rare intrusion into one of India’s largest generic‑drug manufacturers.
The episode highlights a growing friction between India’s pharmaceutical giants and tax authorities, who have intensified scrutiny of import documentation amid a broader effort to curb revenue leakage. Cipla, a stalwart of the domestic drug market, has historically navigated complex customs regimes, and this latest probe underscores the delicate balance between aggressive market expansion and compliance with evolving fiscal policies.
In practical terms, the raid is unlikely to disrupt Cipla’s supply chain, as the company has pledged that operations will continue uninterrupted. However, the public nature of the search may temper investor sentiment and prompt other manufacturers to reassess their import classification practices, potentially leading to a short‑term slowdown in the entry of certain high‑value medicines into the Indian market.
Comments 0